JointHealth™ express   November 18, 2016

ACR News: New Treatment opportunities in axial spondyloarthritis

Good news for Arthritis Consumer Experts (ACE) members and subscribers who live with a form of ankylosing spondylitis. Within the arthritis research world, the field of ankylosing spondylitis is rapidly progressing, and very exciting new discoveries are being made. At the American College of Rheumatology (ACR) annual meeting, Dr. Dirk Elewaut, Professor of Rheumatology and Immunology and Chair of the Department of Rheumatology at Ghent University Hospital, Belgium, discussed the importance of gut inflammation in spondyloarthritis.

“So called ‘microscopic gut inflammation’ seems to be very important in determining a patient’s disease severity and outcome as it represents an important risk factor for the development of Crohn’s disease as well as for evolution to ankylosing spondylitis,” said Dr. Elewaut. “New therapies are emerging in the field of both spondyloarthritis and inflammatory bowel diseases with potentially positive impact on treating gut and joint disease. A better understanding of the role of gut inflammation in spondyloarthritis is therefore very important for rheumatologists and their patients.”

In 2017, ACE will launch JointHealth™ Education AS to help patients with the disease learn how to improve their communication with their rheumatologist to get better treatment outcomes. The course will feature lessons, quizzes and coaching videos covering the key pieces of information you need to have the kind of office visit both you and your rheumatologist want.